

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-27 (Canceled).

Claim 28 (Currently amended): A composition suitable for local, non-systemic administration of a drug to a body and directly to tissue within a body cavity having been subjected to a surgical procedure, said composition consisting of a biodegradable polymer in a form selected from the group consisting of film, foam, fibers and filaments, Tranilast or an analog thereof in an amount effective to inhibit formation of post-operative adhesions upon local, non-systemic administration of said composition to said tissue, and optionally an additional therapeutic agent in an amount effective to provide the therapeutic effect intended by administration of said therapeutic agent,

wherein said Tranilast analog is selected from the group consisting of N-(2-Acetyl-4,5-dimethoxyphenyl)-4-((phenylamino)carbonylamino)phenyl)-formamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-2-(4-((phenylamino)carbonylamino)phenyl)ethanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-((phenylamino)carbonylamino)phenyl)prop-2-enamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-((phenylamino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-4-(4-((phenylamino)carbonyl amino)phenyl)butanamide, N-(2-Acetyl-4,5-di-methoxyphenyl)-3-(4-(phenylcarbonylamino)carbonylamino)phenyl)-propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(2-phenylacetyl-amino)-phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(phenoxy-carbonyl-amino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxy-phenyl)-3-(4-(((2-nitro-phenyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxy-phenyl)-3-(4-(((3-nitrophenyl)amino)carbonylamino)phenyl)propanamide, N-(2-

Acetyl-4,5-dimethoxyphenyl)-3-(4-(((4-nitrophenyl)amino)carbonylamino)phenyl)-propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((2-aminophenyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((3-aminophenyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((4-aminophenyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((4-fluorophenyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((4-acetylphenyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((4-methylphenyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((4-methoxyphenyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((3,4,5-trimethoxyphenyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-(((4-pyridyl)amino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-((benzylamino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-((butylamino)carbonylamino)phenyl)propanamide, N-(2-Acetyl-4,5-dimethoxyphenyl)-3-(4-((cyclohexylamino)carbonylamino)phenyl)propanamide, and a potassium, sodium, calcium and magnesium salt of Tranilast; in an amount effective to inhibit formation of post-operative adhesions upon local, non-systemic administration of said composition to said tissue, a biodegradable polymer in a form selected from the group consisting of film, foam, fibers and filaments, suitable for local, non-systemic administration of said Tranilast or analog thereof, and optionally a therapeutic agent in an amount effective to provide the therapeutic effect intended by administration of said therapeutic agent.

Claim 29 (Canceled).

Claim 30 (Previously presented) The composition of claim 28 wherein said biodegradable polymer is selected from the group consisting of poloxamers, poly(orthoester)s, poly(vinyl alcohol)s, poly(anhydride)s, poly(methacrylate)s,

poly(methacrylamide)s, anionic carbohydrate polymers, poly(hydroxybutyric acid)s, polyacetals, poly(1-lactide), poly(DL-lactide), poly(DL-lactide-co-glycolide)s, poly(1-lactide-co-glycolide)s, poly(ε-caprolactone), polyglycolide, poly(p-dioxanone)s, poly(trimethylene carbonate), poly(alkylene diglycolate)s, poly(oxaester)s, poly(oxamide)s and glyceride polymers.

Claim 31 (Original): The composition of claim 28 wherein said composition provides for single dose administration of said Tranilast or analog thereof.

Claim 32 (Previously presented): The composition of claim 28 wherein said composition provides for sustained release of said Tranilast or analog thereof.

Claim 33 (Canceled).

Claim 34 (Original): The composition of claim 28 comprising from about 0.01 milligram Tranilast or analog thereof per kilogram of the body to about 3,000 milligram Tranilast or analog thereof per kilogram of the body.

Claims 35-38 (Canceled).

Claim 39 (Previously presented): The composition of claim 28 wherein said biodegradable polymer is selected from the group consisting of hyaluronic acids, collagens, pluronics, chitin, chitosans, dextrans, glucoses, carbohydrates, gelatins, glycosaminoglycans, alginates, starches and polypeptides.

Claim 40 (Canceled).

Claim 41 (Currently amended): The composition of claim 28 wherein said therapeutic agent is present and is selected from the group consisting of an anti-

U.S. Serial No. 10/797,367
Response dated: April 8, 2010
Response to Office Action dated January 8, 2010

~~platelet~~, an anti-fibrotic, an anti-inflammatory, an anti-proliferative and an agent that inhibits collagen synthesis.